
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Protecting Sensitive Information in Life Sciences Organizations: Top Three Misconceptions that Put Companies at Risk-Brainloop Whitepaper






